Position in JANX
as of Mar 31, 2026
· filed May 15, 2026
Position Value
$16,503,331
+$15,267,003 QoQ
Shares Held
1,187,290
+1225.3% QoQ
Ownership
1.95%
of shares outstanding
% of Portfolio
0.34%
of 13F equity value
Holder Rank
—
not a current holder
Holding Since
Dec 2025
2 quarters on record
Voting authority
Sole 100%
Shared 0%
None 0%
Common Shares in JANX Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Mar 31, 2026Deep Track Capital, LP holds $4,185,471,777 across 55 Biotechnology names. JANX ranks #49 (0.4% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | IMVT |
Immunovant, Inc.
|
11,526,971 | $286,329,959 | |
| 2 | TARS |
Tarsus Pharmaceuticals, Inc.
|
3,600,000 | $252,540,000 | |
| 3 | PCVX |
Vaxcyte, Inc.
|
4,300,000 | $249,873,000 | |
| 4 | GPCR |
Structure Therapeutics Inc.
|
4,279,848 | $206,288,673 | |
| 5 | AXSM |
Axsome Therapeutics, Inc.
|
1,100,000 | $185,922,000 | |
| 6 | APLS |
Apellis Pharmaceuticals, Inc.
|
4,532,374 | $182,337,406 | |
| 7 | OCUL |
Ocular Therapeutix, Inc
|
19,686,282 | $166,742,808 | |
| 8 | VERA |
Vera Therapeutics, Inc.
|
4,106,067 | $165,187,075 |
All Filings in JANX
Export CSV
2 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-03-31 | $16,503,331 | 1,187,290 | Shares | Sole | 2026-05-15 | |
| 2025-12-31 | $1,236,328 | 89,589 | Shares | Sole | 2026-02-13 | |
| No filing history on record for this holder in this stock. | ||||||